These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19110596)

  • 21. Comparison of effectiveness of biosimilar filgrastim (Nivestim™), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study.
    Brito M; Esteves S; André R; Isidoro M; Moreira A
    Support Care Cancer; 2016 Feb; 24(2):597-603. PubMed ID: 26111956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.
    Park KH; Lee S; Park JH; Kang SY; Kim HY; Park IH; Park YH; Im YH; Lee HJ; Park S; Lee SI; Jung KH; Kim YS; Seo JH
    Support Care Cancer; 2017 Feb; 25(2):505-511. PubMed ID: 27709313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mobilization of hematopoietic progenitor cells with a combination of docetaxel, adriamycin, 5-fluorouracil and filgrastim in breast cancer patients.
    Pérez-Calvo J; Fernández-Hidalgo O; Subirá ML; Martín-Algarra S; Salgado E; Brugarolas A
    Haematologica; 2001 Jan; 86(1):100-1. PubMed ID: 11146579
    [No Abstract]   [Full Text] [Related]  

  • 24. A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel.
    Gladkov O; Moiseyenko V; Bondarenko IN; Shparyk Y; Barash S; Adar L; Avisar N
    Oncologist; 2016 Jan; 21(1):7-15. PubMed ID: 26668251
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Filgrastim post-chemotherapy mobilizes more CD34+ cells with a different antigenic profile compared with use during steady-state hematopoiesis.
    Möhle R; Pförsich M; Fruehauf S; Witt B; Krämer A; Haas R
    Bone Marrow Transplant; 1994 Nov; 14(5):827-32. PubMed ID: 7534163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.
    Basser RL; To LB; Begley CG; Maher D; Juttner C; Cebon J; Mansfield R; Olver I; Duggan G; Szer J; Collins J; Schwartz B; Marty J; Menchaca D; Sheridan WP; Fox RM; Green MD
    J Clin Oncol; 1998 May; 16(5):1899-908. PubMed ID: 9586908
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
    Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
    Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of dose-dense docetaxel and doxorubicin with or without sargramostim in patients with metastatic breast cancer.
    Montero A; Booser D; Esparza-Guerra L; Murray J; Rosales M; Hortobagyi G; Valero V
    Drugs R D; 2005; 6(5):299-305. PubMed ID: 16128600
    [No Abstract]   [Full Text] [Related]  

  • 29. Effectiveness of biosimilar filgrastim vs. original granulocyte colony-stimulating factors in febrile neutropenia prevention in breast cancer patients.
    Puértolas I; Frutos Pérez-Surio A; Alcácera MA; Andrés R; Salvador MDT
    Eur J Clin Pharmacol; 2018 Mar; 74(3):315-321. PubMed ID: 29152672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Feasibility and kinetics of CD34
    Takhar H; Mislang AR; Singhal N; Brown MP
    Asia Pac J Clin Oncol; 2017 Feb; 13(1):79-86. PubMed ID: 27649817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effectiveness of Leukostim, a Russian preparation of granulocyte colony-stimulating factor, in the treatment of chemotherapy-induced neutropenia in patients with malignant tumors].
    Korman DB; Boronovskaia LE; Maslova IA; Andreeva EV; Seregina GV
    Vopr Onkol; 2008; 54(5):639-42. PubMed ID: 19069482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
    von Minckwitz G; Raab G; Caputo A; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Kaufmann M
    J Clin Oncol; 2005 Apr; 23(12):2676-85. PubMed ID: 15837982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
    Gatzemeier U; Ciuleanu T; Dediu M; Ganea-Motan E; Lubenau H; Del Giglio A
    J Thorac Oncol; 2009 Jun; 4(6):736-40. PubMed ID: 19404210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Life-threatening complications from doxorubicin-docetaxel chemotherapy for breast cancer.
    Martin M; Vogel C; Crown J; Mackey J
    JAMA; 2005 Nov; 294(17):2166; author reply 2166-7. PubMed ID: 16264153
    [No Abstract]   [Full Text] [Related]  

  • 35. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
    Frasci G; D'Aiuto G; Thomas R; Comella P; Di Bonito M; Lapenta L; D'Aiuto M; Botti G; Vallone P; De Rosa V; D'Aniello R; Giordano R; Comella G
    Oncology; 2005; 68(4-6):391-7. PubMed ID: 16020968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of stimulating effect of glycyram and D-glucuronic acid on granulocytopoiesis suppression by 5-fluorouracil.
    Dygai AM; Zhdanov VV; Miroshnichenko LA; Zyuz'kov GN; Udut EV; Simanina EV; Stavrova LA; Khrichkova TY; Reykhart DV; Agafonov VI
    Bull Exp Biol Med; 2013 Jun; 155(2):207-11. PubMed ID: 24130991
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support.
    Wolff AC; Jones RJ; Davidson NE; Jeter SC; Stearns V
    J Clin Oncol; 2006 May; 24(15):2392-4; author reply 2394-5. PubMed ID: 16710041
    [No Abstract]   [Full Text] [Related]  

  • 38. [Persistent granulocytosis and hyperuricemia after a single G-CSF injection (Filgrastim) in treatment of chemotherapy-induced myelosuppression in metastatic breast carcinoma].
    Hofmann M; Mahlke M; Casper F; Brockerhoff P
    Zentralbl Gynakol; 1995; 117(6):314-6. PubMed ID: 7544054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biweekly docetaxel-irinotecan with filgrastim support in pretreated breast and non-small-cell lung cancer patients. A phase I study.
    Frasci G; Comella P; Thomas R; Di Bonito M; Lapenta L; Capasso I; Botti G; Vallone P; De Rosa V; D'Aiuto G; Comella G
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):25-32. PubMed ID: 14513281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.